-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $130

Benzinga·04/17/2026 13:42:34
Listen to the news
RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $135 to $130.